Advanced Cell Technology, Inc. (OTC Bulletin Board: ACTC) together with colleagues announced today the development of five human embryonic stem cell (hESC) lines without the destruction of embryos. These new results have the potential to end the ethical debate surrounding the use of embryos to derive stem cells. In fact, the NIH report to the President refers to this technology as one of the viable alternatives to the destruction of embryos.
The new method will be published today in the journal Cell Stem Cells, published by Cell Press. The peer-reviewed technique was initially carried out by ACT scientists under the direction of Robert Lanza, M.D., and then independently replicated by scientists on the West Coast. Single cells were removed from the embryos using a technique similar to preimplantation genetic diagnosis (PGD). The biopsied embryos continued to develop normally and were then frozen. The cells that were removed were cultured utilizing a proprietary methodology that recreates the optimal developmental environment, which substantially improved the efficiency of deriving stem cells to rates comparable to using the traditional approach of deriving stem cells from the inner cell mass of a whole blastocyst stage embryo. The stem cells were genetically normal and differentiated into cell types of all three germ layers of the body, including blood cells, neurons, heart cells, cartilage, and other cell types of potentially therapeutic significance.
“This is a working technology that exists here and now,” said Robert Lanza, M.D., Chief Scientific Officer at Advanced Cell Technology and senior author of the paper. “It could be used to increase the number of stem cell lines available to federal researchers immediately. We could send these cells out to researchers tomorrow. If the White House approves this new methodology, researchers could effectively double or triple the number of stem cell lines available within a few months. Too many needless deaths continue to occur while this research is being held up. I hope the President will act now and approve these stem cell lines quickly.”
The paper published today also addresses several other important issues. First, the stem cells were derived without culturing multiple cells from each embryo together, and at efficiency levels similar to that reported for conventional stem cell derivation techniques using blastocysts. Second, it addresses ethical objections that the derivation system required co-culture with hESCs from other embryos that were destroyed. The current study demonstrates that hESC co-culture is not an essential part of the derivation procedure. The stem cell lines generated in the present study appear to have the same characteristics as other hESC lines, including expression of the same markers of pluripotency, self-renewing capacity, genetic stability, and ability to differentiate into derivatives of all three germ layers of the body.
“We are excited that our new method for generating human embryonic stem cell lines without the destruction of embryos has been accepted for inclusion by such a prestigious publication,” said William M. Caldwell IV, Chairman and CEO of Advanced Cell Technology. “This new approach addresses the President Bush’s ethical concerns. We are hopeful that the NIH will consider this new approach for federal funding. We believe that such consideration reflects the desire of the American people to bring therapies derived from stem cell research to patients with few or no alternatives.”
Other contributors to the study and publication include Young Chung and Irina Klimanskaya, Sandy Becker, Tong Li, Marc Maserati, and Shi-Jiang Lu of Advanced Cell Technology; Tamara Zdravkovic, Olga Genbacev, and Susan Fisher of the University of California, San Francisco; and Dusko Ilic and Ana Krtolica of StemLifeLine.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.